Literature DB >> 18038883

When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?

Manuela Beda1, Umberto Basso, Cristina Ghiotto, Silvio Monfardini.   

Abstract

We report the case of a woman with HER2-positive metastatic breast cancer who achieved prolonged complete remission of multiple liver metastases after treatment with weekly trastuzumab plus paclitaxel but relapsed in the brain soon after stopping trastuzumab maintenance therapy which had been prosecuted for almost three years. In the absence of randomized trials, the optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains questionable.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18038883     DOI： 10.1177/030089160709300514

Source DB:  PubMed          Journal:  Tumori        ISSN： 0300-8916


  10 in total

1.  Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?

Authors:  Amy Hsieh; Ken Pittman; William K Patterson; Amanda Townsend
Journal:  BMJ Case Rep       Date:  2015-06-03

2.  Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report.

Authors:  John Syrios; Anna Dokou; Nicolas Tsavaris
Journal:  J Med Case Rep       Date:  2010-12-10

Review 3.  Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Authors:  Isabel Ihnenfeld Arciénega; Patrick Imesch; Daniel Fink; Konstantin J Dedes
Journal:  Target Oncol       Date:  2014-12-17       Impact factor: 4.493

Review 4.  Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission.

Authors:  R Haq; P Gulasingam
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

5.  Long-responders to anti-HER2 therapies: A case report and review of the literature.

Authors:  Luca Cantini; Mirco Pistelli; Agnese Savini; Lucia Bastianelli; Arianna Della Mora; Filippo Merloni; Michela Burattini; Rossana Berardi
Journal:  Mol Clin Oncol       Date:  2017-11-08

6.  Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.

Authors:  Isabell Witzel; Volkmar Müller; Wolfgang Abenhardt; Manfred Kaufmann; Winfried Schoenegg; Andreas Schneeweis; Fritz Jänicke
Journal:  BMC Cancer       Date:  2014-11-04       Impact factor: 4.430

7.  More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.

Authors:  Florin Badulescu; Adriana Badulescu; Doru Paul; Carmen Florina Popescu; Cristina Florescu
Journal:  Onco Targets Ther       Date:  2014-10-17       Impact factor: 4.147

8.  Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors.

Authors:  Satoru Tanaka; Ayana Ikari; Toshikatsu Nitta; Tetsuya Horiuchi
Journal:  Oxf Med Case Reports       Date:  2017-07-06

9.  Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Authors:  Matteo S Carlino; Vito Vanella; Christina Girgis; Diana Giannarelli; Alex Guminski; Lucia Festino; Richard F Kefford; Alexander M Menzies; Georgina V Long; Paolo A Ascierto
Journal:  Br J Cancer       Date:  2016-10-06       Impact factor: 7.640

10.  Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.

Authors:  Haruko Takuwa; Wakako Tsuji; Fumiaki Yotsumoto
Journal:  Int J Surg Case Rep       Date:  2018-10-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.